Spyre Therapeutics SYRE
NASDAQ SYRE
$93.19 +3.26 (+3.63%)
At close: Oct 2, 2026 · 4:00 PM EDT

Spyre Therapeutics (SYRE) Cash from Financing Activities (2015 - 2026)

Updated

Spyre Therapeutics (SYRE) posted Cash from Financing Activities of $432.6 million for Q2 2026, compared with $731,000 a year earlier.

Analysis

Spyre Therapeutics (SYRE) Cash from Financing Activities (2015 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Cash from Financing Activities at Spyre Therapeutics was $753.03 million, up 214.8% year-over-year; for FY2025, it was $309.03 million, down 24.8% from FY2024.

  • Annual Cash from Financing Activities shows a five-year compound annual growth rate of 14.9% (FY2020 to FY2025).
  • In prior years, Spyre Therapeutics' Cash from Financing Activities was $410.91 million in FY2024 (+13.8%), $361.08 million in FY2023 (+746.0%), $42.68 million in FY2022 and $1.39 million in FY2021 (-99.1%).
  • The Q2 2026 figure stands as the highest quarterly Cash from Financing Activities in data going back to Q1 2015.
  • On a year-over-year basis, Cash from Financing Activities increased in three of the last four quarters, with growth averaging 19.9%.
  • The strongest year-over-year quarter for Cash from Financing Activities in the past five years was Q2 2023, with growth of 390.6%; the weakest was Q1 2025, with a decline of 99.9%.
  • According to Business Quant data, Cash from Financing Activities for the three prior quarters was $12.26 million (Q1 2026), $312.81 million (Q4 2025) and -$4.64 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 8.43 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn -8.78 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn -5.05 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 1.76 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn -2.02 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn -47.00 Mn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn -1.48 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn 2.34 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn -3.66 Bn
10 Spyre Therapeutics 7.92 Bn 7.92 Bn - 432.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 432.60 Mn
Mar 31, 2026 12.26 Mn
Dec 31, 2025 312.81 Mn
Sep 30, 2025 -4.64 Mn
Jun 30, 2025 731,000.00
Mar 31, 2025 125,000.00
Dec 31, 2024 225.60 Mn
Sep 30, 2024 12.78 Mn
Jun 30, 2024 360,000.00
Mar 31, 2024 172.17 Mn
Dec 31, 2023 163.61 Mn
Sep 30, 2023 -12.53 Mn
Jun 30, 2023 209.99 Mn
Mar 31, 2023 10,000.00
Dec 31, 2022 -8,000.00
Sep 30, 2022 -130,000.00
Jun 30, 2022 42.80 Mn
Mar 31, 2022 12,000.00
Dec 31, 2021 80,000.00
Sep 30, 2021 1.14 Mn
API Access

Spyre Therapeutics Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=SYRE&period=max&api_key=YOUR_API_KEY